Anzeige
Mehr »
Mittwoch, 13.05.2026 - Börsentäglich über 12.000 News
Kann Inspiration Mining die nächste 1.000 % Chance werden? Das Bohrprogramm startet in wenigen Tagen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0CBDJ | ISIN: KYG8167W1380 | Ticker-Symbol: SMZ1
Tradegate
12.05.26 | 17:21
0,637 Euro
-0,23 % -0,002
Branche
Biotechnologie
Aktienmarkt
HANG SENG
1-Jahres-Chart
SINO BIOPHARMACEUTICAL LTD Chart 1 Jahr
5-Tage-Chart
SINO BIOPHARMACEUTICAL LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,6230,64412.05.
0,6260,65012.05.

Aktuelle News zur SINO BIOPHARM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SINO BIOPHARM Aktie jetzt für 0€ handeln
DiGSK and SBP Group team up to advance bepirovirsen launch in China3
DiG Sachs Raises SBP GROUP TP to HKD8.05, Maintains Buy on Introduction of GSK Hepatitis B Drug6
MoGSK strikes agreement with China's SBP Group, launches final tranche of buyback programme3
MoSBP GROUP Forms Exclusive Strategic Partnership with GlaxoSmithKline to Accelerate Mainland Launch of bepirovirsen4
MoSBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - ENTERING INTO AN EXCLUSIVE STRATEGIC COLLABORATION WITH GSK4
DoSBP GROUP (01177): NEXT DAY DISCLOSURE RETURN1
DoSBP GROUP's Category 1 Innovative Drug M701 NDA Accepted3
DoSBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR M701 "CD3/EPCAM BISPECIFIC ANTIBODY"2
DoSBP GROUP CCR8 Monoclonal Antibody for Gastric Cancer Completes First Patient Enrollment in Clinical Trial4
DoSBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLMENT IN THE PHASE III REGISTRATIONAL CLINICAL TRIAL OF CAFELKIBART "CCR8 MONOCLONAL ANTIBODY" ...2
06.05.SBP GROUP: Kumoxili Capsules Approved in Mainland for 2nd Indication7
06.05.SBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF CULMERCICLIB CAPSULE "CDK2/4/6 INHIBITOR" FOR FIRST-LINE TREATMENT OF BREAST CANCER APPROVED ...2
30.04.SBP GROUP (01177): NEXT DAY DISCLOSURE RETURN2
29.04.SBP GROUP (01177): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT4
29.04.SBP GROUP (01177): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS3
29.04.SBP GROUP (01177): NOTIFICATION LETTER AND REPLY FORM FOR REGISTERED SHAREHOLDERS2
29.04.SBP GROUP (01177): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING (OR ANY ADJOURNMENT OR POSTPONEMENT THEREOF)1
29.04.SBP GROUP (01177): NOTICE OF ANNUAL GENERAL MEETING2
29.04.SBP GROUP (01177): GENERAL MANDATES TO ISSUE AND BUY BACK SHARES; RE-ELECTION OF DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING1
29.04.SBP GROUP (01177): PROPOSED STEP-DOWN AND RETIREMENT OF DIRECTORS2
Weiter >>
84 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1